MRK241011P100000
- 0.02
- -0.05-71.43%
Merck & Co Newsroom
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Merck & Co Analyst Ratings
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $132
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $136
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $132
TD Cowen Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck Price Target Cut to $140.00/Share From $142.00 by Barclays
Merck & Co Analyst Ratings
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co Analyst Ratings
Gritstone Downgraded by Jones, B. Riley Over Cancer Vaccine Data
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $142
Barclays Reaffirms Their Buy Rating on Merck & Company (MRK)
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $145
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
BofA Securities Initiates Merck & Co(MRK.US) With Buy Rating, Announces Target Price $140
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Moderna Continues to Decline as Oppenheimer Latest to Downgrade
Moderna Extends Losses as R&D Day Updates Lead to Downgrades